<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726800</url>
  </required_header>
  <id_info>
    <org_study_id>2019-04884</org_study_id>
    <nct_id>NCT04726800</nct_id>
  </id_info>
  <brief_title>Circulating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study</brief_title>
  <acronym>CITCCA</acronym>
  <official_title>A Pilot Study Investigating the Feasibility to Perform Prospective Circulating Tumor DNA (ctDNA) Profiling in Patients With Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Martling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In clinical practice, there are currently no biomarkers that can guide colorectal cancer&#xD;
      treatment in the primary and curative setting. Improved biomarker-based adjuvant treatments&#xD;
      would be of greatest value in order to reduce the risk of relapse. There are reasons to&#xD;
      believe that measurements of circulating tumor DNA (ctDNA) in plasma could be used to monitor&#xD;
      minimal residual disease after surgery. To address this question, a pilot study was conducted&#xD;
      with the purpose to demonstrate the feasibility to perform prospective profiling of ctDNA in&#xD;
      a cohort of patients with colorectal cancer stage I-III using the already created Nordic&#xD;
      infrastructure for clinical research built up for the ALASCCA trial. If the pilot study&#xD;
      proves successful, a large randomised controlled Nordic multicenter study is planned where&#xD;
      patients with positive ctDNA 4-6 weeks after radical surgery will be randomised to&#xD;
      chemotherapy and/or a biologic agent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and logistics of measuring ctDNA</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of positive ctDNA postoperatively in relation to tumour stage and oncological outcome.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of positive ctDNA preoperative converted to negative postoperatively.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants will be asked to donate 30ml blood before surgery (baseline), after surgery at&#xD;
      4-6 weeks, 3-, 6-, 12- and 24 months postoperatively to measure cell-free DNA (cfDNA) in&#xD;
      plasma.&#xD;
&#xD;
      All biospecimens will be shipped to the biobank at Karolinska Institutet for further&#xD;
      processing. DNA will be extracted from tumor tissue and whole blood. Targeted sequencing of&#xD;
      tumor tissue and germline DNA will be performed using in solution hybridization-based capture&#xD;
      at Clinical Genomics, SciLife Lab, Stockholm. Blood in the CITCCA pilot will be profiled&#xD;
      prospectively with a two-week turnover, using the ProBio infrastructure, mimicking a real&#xD;
      clinical scenario where minimal residual disease (MRD) information will be available in a&#xD;
      condense report format.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The pilot study will include patients diagnosed with colorectal cancer stage I-III invited&#xD;
        to participate in the ALASCCA study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Colon or rectal cancer tumor stage I-III planned for radical surgery&#xD;
&#xD;
          -  Clean Colonoscopy or Computed Tomography (CT) colon within 3 months preoperatively or&#xD;
             postoperatively but before randomization&#xD;
&#xD;
          -  Patient able to understand and sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Other cancers (excluding colorectal cancer or other skin cancer than melanoma) within&#xD;
             3 years from screening&#xD;
&#xD;
          -  Significant medical illness that would interfere with study participation&#xD;
&#xD;
          -  Pregnancy or breastfeeding females&#xD;
&#xD;
          -  Current participation in another clinical trial that will be in conflict with the&#xD;
             present study&#xD;
&#xD;
          -  Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude,&#xD;
             inability to return for subsequent visits) and/or otherwise considered by the&#xD;
             Investigator to be unlikely to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Martling, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Martling, Professor</last_name>
    <phone>+46851770000</phone>
    <email>anna.martling@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akershus Univeristy Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skaraborg Hospital</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Capio Sankt Göran Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Danderyd University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ersta Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Martling, Professor</last_name>
      <phone>+46851770000</phone>
      <email>anna.martling@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anna Martling</investigator_full_name>
    <investigator_title>Professor, Senior Consultant Surgeon</investigator_title>
  </responsible_party>
  <keyword>predictive marker</keyword>
  <keyword>prognostic marker</keyword>
  <keyword>ctDNA</keyword>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

